Improved oral bioavailability of cyclosporin A in male Wistar rats -: Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension

被引:35
作者
González, RCB [1 ]
Huwyler, J [1 ]
Walter, I [1 ]
Mountfield, R [1 ]
Bittner, B [1 ]
机构
[1] F Hoffmann La Roche & Co Ltd, Discovery KMPK, Div Pharmaceut, CH-4070 Basel, Switzerland
关键词
cyclosporin A; Solutol HS 15; self-dispersing formulation; microsuspension; oral bioavailability;
D O I
10.1016/S0378-5173(02)00339-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oral bioavailability of the highly lipophilic and poorly water-soluble immunosuppressive agent cyclosporin A (CyA) in two different formulations was investigated in male Wistar rats. An aqueous microsuspension and a self-dispersing formulation composed of the surface-active ingredients Solutol HS 15:1-abrafil M2125CS:oleic acid = 721 (v/v/v) were administered to the animals at a dose level of 20 mg/kg. In order to calculate the absolute oral bioavailability, CyA was additionally administered intravenously at 10 mg/kg as microsuspension. It as found that the oral bioavailability of CyA in the Solutol HS 15-based formulation was twofold higher as compared to the microsuspension (69.9+/-2.8 vs. 35.7+/-3.3%, P = 0.001). By contrast. the time to reach maximum plasma concentration and the terminal half-life (t(1/2)) did not differ significantly with the different formulations (t(max): 7.0 +/- 1.0 vs. 6.3 +/- 1.7 h: t(1/2): 20.5 +/- 2.9 vs. 16.7 +/- 4.7 h). In vitro solubility experiments demonstrated a marked increase in the aqueous solubility of CyA in the presence of the self-dispersing formulation as compared to the micronized powder alone (solubility after 120 min at 37 degreesC: 136 vs. 23.2 mug/ml in human gastric juiced 133 vs. 10.8 mug/ml in simulated intestinal juice). Most likely. the enhanced systemic exposure of CyA in the self-dispersing formulation was caused by improved Solubility of CyA in the gastrointestinal fluids in the presence of the surface-active ingredients. Additional factors that may have contributed to increased oral bioavailability are inhibition of metabolism and/or transport processes as well as permeability enhancement by the co-administered excipients. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:143 / 151
页数:9
相关论文
共 31 条
[1]  
Bittner B, 2002, CURR OPIN DRUG DI DE, V5, P59
[2]  
Buckingham LE, 1996, INT J CANCER, V65, P74
[3]  
Burcham DL, 1997, BIOPHARM DRUG DISPOS, V18, P737, DOI 10.1002/(SICI)1099-081X(199711)18:8<737::AID-BDD59>3.0.CO
[4]  
2-9
[5]   The effect of water-soluble vitamin E On cyclosporine pharmacokinetics in healthy volunteers [J].
Chang, T ;
Benet, LZ ;
Hebert, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (03) :297-303
[6]   THE ABSORPTION SITE OF CYCLOSPORINE IN THE HUMAN GASTROINTESTINAL-TRACT [J].
DREWE, J ;
BEGLINGER, C ;
KISSEL, T .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 33 (01) :39-43
[7]   CYCLOSPORINE CLINICAL PHARMACOKINETICS [J].
FAHR, A .
CLINICAL PHARMACOKINETICS, 1993, 24 (06) :472-495
[8]   Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: In vitro in vivo correlation [J].
Fricker, G ;
Drewe, J ;
Huwyler, J ;
Gutmann, H ;
Beglinger, C .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (07) :1841-1847
[9]   A new microemulsion formulation of cyclosporin - Pharmacokinetic and clinical features [J].
Friman, S ;
Backman, L .
CLINICAL PHARMACOKINETICS, 1996, 30 (03) :181-193
[10]   Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs [J].
Gershanik, T ;
Benita, S .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) :179-188